FDA Determines Regulatory Review Period for DIFFERIN Topical Gel Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of DIFFERIN Topical Gel, a human drug product, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.